グルカゴン様ペプチド-1（GLP-1）アゴニストの世界市場レポート2024-2030

QY Research > レポート一覧 > 薬品及びサプリメント > グルカゴン様ペプチド-1（GLP-1）アゴニストの世界市場レポート2024-2030

英文タイトル： Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2030

レポートID：39737
発表時期：2024-11-16
訪問回数：800
ページ数：127
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：145
レポートカテゴリ：薬品及びサプリメント

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=153.40円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=153.40円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

本報告書はグルカゴン様ペプチド-1（GLP-1）アゴニスト市場規模の世界市場の概要を紹介します。2020~2024年の歴史的な市場収益データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。レポートはグルカゴン様ペプチド-1（GLP-1）アゴニストの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはグルカゴン様ペプチド-1（GLP-1）アゴニストのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にグルカゴン様ペプチド-1（GLP-1）アゴニスト市場を分類しています。本研究に含まれる主な企業は：Novo Nordisk、 Eli Lilly、 AstraZeneca、 Sanofi、 GSK、 Hanson、 Shanghai Benemae

地域別市場区分、地域別分析は以下の通り：
アメリカとカナダ
中国
アジア
ヨーロッパ
中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other

用途別の市場セグメント：
Diabetes
Obesity

本レポートの詳細内容
世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、グルカゴン様ペプチド-1（GLP-1）アゴニストタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。レポートは主要企業のグルカゴン様ペプチド-1（GLP-1）アゴニスト収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、グルカゴン様ペプチド-1（GLP-1）アゴニスト市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

グルカゴン様ペプチド-1（GLP-1）アゴニストのレポートは2020年から2031年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：グルカゴン様ペプチド-1（GLP-1）アゴニストのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2020～2031）

第2章：グルカゴン様ペプチド-1（GLP-1）アゴニストの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2020～2031）

第3章グルカゴン様ペプチド-1（GLP-1）アゴニスト企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2020～2031）

第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2025）

第5章：グルカゴン様ペプチド-1（GLP-1）アゴニストの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）

第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2020～2031）

第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2020～2031）

第8章：中国の種類別、および用途別、各セグメントの収益。（2020～2031）

第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2020～2031）

第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2020～2031）

第11章：グルカゴン様ペプチド-1（GLP-1）アゴニストの主要企業の概要を提供し、製品の説明と仕様、グルカゴン様ペプチド-1（GLP-1）アゴニストの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2020～2025）

第12章：アナリストの見解/結論

概要

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ 108120 million in 2024 to US$ 401670 million by 2030, at a Compound Annual Growth Rate (CAGR) of 24.5% during the forecast period.

The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.

Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.

Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.

Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.

Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.

Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.

Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.

Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.

Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.

Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.

Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.

Report Includes
This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.

Market Segmentation
By Company
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae

Segment by Type
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other

Segment by Application
Diabetes
Obesity

Segment by region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Australia
Europe
Germany
France
U.K.
Italy
Russia

Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

総目録

1 Study Coverage
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
1.2 Market by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Dulaglutide
1.2.3 Exenatide
1.2.4 Liraglutide
1.2.5 Benaglutide
1.2.6 Other
1.3 Market by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Diabetes
1.3.3 Obesity
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Executive Summary
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Estimates and Forecasts 2019-2030
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
2.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024)
2.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030)
2.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2030)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts 2019-2030
2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
2.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024)
2.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030)
2.4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America

3 Competition by Manufacturers
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2019-2024)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists in 2023
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers
3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2019-2024)
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023
3.3 Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2021 VS 2022
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Manufacturers (2019-2024)
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Offered and Application
3.8 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historical Sales by Type (2019-2024)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Sales by Type (2025-2030)
4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historical Revenue by Type (2019-2024)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Revenue by Type (2025-2030)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type
4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2024)
4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2025-2030)

5 Market Size by Application
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historical Sales by Application (2019-2024)
5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Sales by Application (2025-2030)
5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historical Revenue by Application (2019-2024)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Revenue by Application (2025-2030)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application
5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2024)
5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2025-2030)

6 US & Canada
6.1 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
6.1.1 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
6.1.2 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
6.2 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
6.2.1 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
6.2.2 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
6.3 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
6.3.1 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
6.3.3 US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
6.3.4 US
6.3.5 Canada

7 Europe
7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
7.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
7.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
7.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
7.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
7.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
7.3.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia

8 China
8.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
8.1.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
8.1.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
8.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
8.2.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
8.2.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)

9 Asia (excluding China)
9.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
9.1.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
9.1.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
9.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
9.2.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
9.2.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
9.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region
9.3.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2030)
9.3.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
9.3.9 Australia

10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
10.1.1 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
10.2.1 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
10.3.1 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries

11 Corporate Profile
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Overview
11.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Overview
11.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Information
11.3.2 AstraZeneca Overview
11.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AstraZeneca Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 GSK
11.5.1 GSK Company Information
11.5.2 GSK Overview
11.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 GSK Recent Developments
11.6 Hanson
11.6.1 Hanson Company Information
11.6.2 Hanson Overview
11.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Hanson Recent Developments
11.7 Shanghai Benemae
11.7.1 Shanghai Benemae Company Information
11.7.2 Shanghai Benemae Overview
11.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai Benemae Recent Developments

12 Industry Chain and Sales Channels Analysis
12.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Chain Analysis
12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
12.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Marketing
12.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels
12.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
12.5 Glucagon Like Peptide-1 (GLP-1) Agonists Customers

13 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
13.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
13.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
13.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

14 Key Findings in the Global Glucagon Like Peptide-1 (GLP-1) Agonists Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

表と図のリスト

List of Tables
 Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Dulaglutide
 Table 3. Major Manufacturers of Exenatide
 Table 4. Major Manufacturers of Liraglutide
 Table 5. Major Manufacturers of Benaglutide
 Table 6. Major Manufacturers of Other
 Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
 Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
 Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2024)
 Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2025-2030)
 Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
 Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
 Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2024)
 Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2025-2030)
 Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2019-2024) & (K Units)
 Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2019-2024)
 Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2019-2024)
 Table 22. Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2021 VS 2022 VS 2023
 Table 23. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers (2019-2024) & (USD/Unit)
 Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2023)
 Table 26. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Base Distribution and Headquarters
 Table 27. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Offered and Application
 Table 28. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
 Table 29. Mergers & Acquisitions, Expansion Plans
 Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2019-2024)
 Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2025-2030)
 Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2019-2024)
 Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2025-2030)
 Table 38. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2024) & (USD/Unit)
 Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2025-2030) & (USD/Unit)
 Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2019-2024)
 Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2025-2030)
 Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2019-2024)
 Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2025-2030)
 Table 48. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2024) & (USD/Unit)
 Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2025-2030) & (USD/Unit)
 Table 50. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 51. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 52. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 53. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 54. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 55. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 56. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 57. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 58. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 59. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 60. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 61. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 62. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 63. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 64. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 65. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 66. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 67. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 68. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 69. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 70. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 71. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 72. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 73. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 74. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 75. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 76. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 77. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 78. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 79. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 80. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 81. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 82. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 83. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 84. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 85. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 86. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 87. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 88. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 89. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 90. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 91. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 92. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 93. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
 Table 94. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
 Table 95. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
 Table 96. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
 Table 97. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 98. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 99. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 100. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 101. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 102. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 103. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 104. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 105. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 106. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 107. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 108. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 109. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 110. Novo Nordisk Company Information
 Table 111. Novo Nordisk Description and Major Businesses
 Table 112. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 113. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 114. Novo Nordisk Recent Developments
 Table 115. Eli Lilly Company Information
 Table 116. Eli Lilly Description and Major Businesses
 Table 117. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 118. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 119. Eli Lilly Recent Developments
 Table 120. AstraZeneca Company Information
 Table 121. AstraZeneca Description and Major Businesses
 Table 122. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 123. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 124. AstraZeneca Recent Developments
 Table 125. Sanofi Company Information
 Table 126. Sanofi Description and Major Businesses
 Table 127. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 128. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 129. Sanofi Recent Developments
 Table 130. GSK Company Information
 Table 131. GSK Description and Major Businesses
 Table 132. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 133. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 134. GSK Recent Developments
 Table 135. Hanson Company Information
 Table 136. Hanson Description and Major Businesses
 Table 137. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 138. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 139. Hanson Recent Developments
 Table 140. Shanghai Benemae Company Information
 Table 141. Shanghai Benemae Description and Major Businesses
 Table 142. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 143. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 144. Shanghai Benemae Recent Developments
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
 Table 148. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
 Table 149. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
 Table 150. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
 Table 151. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
 Table 152. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources


List of Figures
 Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
 Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type: 2023 & 2030
 Figure 4. Dulaglutide Product Picture
 Figure 5. Exenatide Product Picture
 Figure 6. Liraglutide Product Picture
 Figure 7. Benaglutide Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application: 2023 & 2030
 Figure 11. Diabetes
 Figure 12. Obesity
 Figure 13. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
 Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2030)
 Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2019-2030) & (K Units)
 Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2030)
 Figure 22. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 23. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 24. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 25. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 26. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 27. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 28. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 29. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 30. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 31. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2023)
 Figure 33. The Glucagon Like Peptide-1 (GLP-1) Agonists Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2023)
 Figure 35. The Top 5 and 10 Largest Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists in the World: Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023
 Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 41. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 42. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 43. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 44. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 45. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 46. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 47. US Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 48. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 55. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 56. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 59. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 61. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 62. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 63. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 64. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 65. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 66. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 67. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 68. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Region (2019-2030)
 Figure 69. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Region (2019-2030)
 Figure 70. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 71. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 72. China Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 73. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 74. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 75. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 76. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 77. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 78. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 79. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 80. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 81. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 82. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 83. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 84. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 85. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 86. GCC Countries Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 87. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain
 Figure 88. Glucagon Like Peptide-1 (GLP-1) Agonists Production Process
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed

以下、関連資料のご紹介